Author’s Disclosure Block: Steve Arshinoff: Alcon, Employment/honoraria/consulting fees, BVI, Employment/honoraria/consulting fees, Bohus Biotech, Employment/honoraria/consulting fees, Rayner, Employment/honoraria/consulting fees, carl Zeiss Meditech, Employment/honoraria/consulting fees; Runjie Bill Shi: none; Brenda Tao: none

Abstract Body
Purpose:To determine the optimal concentration for intracameral moxifloxacin (ICM) to preventpost-operative endophthalmitis (POE).last year we presented the reasoning to increase the dose of ICM administered for PCR and secondary IOL cases. To accommodate this need, the moxifloxacin solution concentration needs to be reevaluated, as the space in the anterior chamber is limited. Study Design: Literature review and mathematical modelling Methods: We adapted our previous mathematical ICM injection model for standard cataract surgery to the varied parameters of routine and PCR cases. We determined a revised solution concentration to optimize ICM administration for all cases. RESULTS: Once PCR occurs, the effective volume of the space requiring antibacterial prophylaxis expands, thus requiring an increased ICM dose to attain a final similar ICM concentration in the AC.Using our previous dilute solution of moxifloxacin required an excessive volume to be administered, which could compromise its prophylactic efficacy. Different concentrations were studied, and an optimal compromise was selected. CONCLUSION:The selected concentration of ICM of 250mg per 0.1 mL was chosen and the reasoning will be explained in detail.